Research and Development Investment: Summit Therapeutics Inc. vs Geron Corporation

Biotech Giants' R&D Surge: A Decade of Innovation

__timestampGeron CorporationSummit Therapeutics Inc.
Wednesday, January 1, 20142070700015635076
Thursday, January 1, 20151783100023943601
Friday, January 1, 20161804700023689111
Sunday, January 1, 20171103300041006114
Monday, January 1, 20181343200051379106
Tuesday, January 1, 20195207200032705593
Wednesday, January 1, 20205148800053274000
Friday, January 1, 20218572700085352000
Saturday, January 1, 20229551800051999000
Sunday, January 1, 202312504600059471000
Loading chart...

Unveiling the hidden dimensions of data

A Decade of Innovation: R&D Investments in Biotech

In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Summit Therapeutics Inc. and Geron Corporation have been at the forefront of this transformative journey. From 2014 to 2023, Geron Corporation's R&D expenses surged by nearly 500%, peaking in 2023. This reflects a strategic focus on pioneering treatments in oncology. Meanwhile, Summit Therapeutics Inc. demonstrated a steady commitment to R&D, with a notable 280% increase from 2014 to 2021, before a slight decline in subsequent years. This trend underscores the dynamic nature of biotech investments, where companies must balance innovation with financial sustainability. As the industry continues to evolve, these investments highlight the relentless pursuit of breakthroughs that could redefine healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025